The Breast Cancer Trials (BCT) Board of Directors have made the difficult decision to cancel BCT’s 42nd Annual Scientific Meeting (ASM) which was due to take place from 22-24 July 2020 in Auckland, New Zealand, due to the current situation concerning the spread of the coronavirus (COVID-19) and the unknown future impact this may have.
We have a duty of care to our members, sponsors, staff, delegates and the wider community, to minimise the risk of further spread of the COVID-19. Collectively the Board felt it was also in the best interests of our members and guests to arrive at this decision now to prevent the potential loss of investment people may make in order to attend the meeting.
Breast Cancer Trials would like to acknowledge the efforts of medical staff working in our health systems in Australia and New Zealand during these unprecedented times. Some of our members, colleagues and friends will be at the front line of treating and managing this virus and our thoughts are with them and their own health and safety, and the safety of their patients and trial participants.
At present Breast Cancer Trials is continuing our clinical trials research and will be closely monitoring the situation to ensure all our trials run as smoothly as possible during this time.
Our priority is the safety of patients, and appropriate measures will be put in place to minimise any risks to trial participants.
For any questions regarding the cancellation of the BCT ASM, please contact the BCT ASM Secretariat at [email protected].